NCT03530683
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
- NCT03530683 ↗
- Terminated
- Pfizer
- Focused
We haven't built an HCP commentary report on NCT03530683 (maplirpacept; maplirpacept plus azacitidine; maplirpacept plus azacitidine plus venetoclax in advanced hematologic malignancies) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03530683 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1a/1b Dose-Escalation and Expansion Trial of TTI-622 in Patients With Advanced Hematologic Malignancies, Including Lymphoma, Leukemia, and Multiple Myeloma
- Phase
- Phase 1
- Status
- Terminated
- Conditions
- Lymphoma; Multiple Myeloma; Acute Myeloid Leukemia; Diffuse Large B-Cell Lymphoma
- Interventions
- Maplirpacept (PF-07901801); Azacitidine; Venetoclax; Carfilzomib; Dexamethasone; Anti-CD20 Targeting agent; Isatuximab
- Arms
- maplirpacept (PF-07901801) Monotherapy · Experimental
- Cohort A: maplirpacept (PF-07901801) + Azacitidine · Experimental
- Cohort B: maplirpacept (PF-07901801) + Azacitidine and Venetoclax · Experimental
- Cohort D1 and D2: maplirpacept (PF-07901801) + an anti-CD20 targeting agent · Experimental
- Cohort E1 and E2: single agent maplirpacept (PF-07901801) · Experimental
- Cohort F1, F2 and F3: maplirpacept (PF-07901801) + isatuximab, carfilzomib and dexamethasone · Experimental
- Cohort C1, C2 and C3: maplirpacept (PF-07901801) + Carfilzomib and Dexamethasone · Experimental
- Enrollment
- 189
- Primary outcomes
- Phase 1a: Number of adverse events (AE) by severity
- Phase 1a: Number of AEs by Frequency
- Phase 1a: Number of participants with Dose-Limiting Toxicities (DLT)
- Phase 1b: Number of adverse events (AE) by severity
- Phase 1b: Number of adverse events (AE) by frequency
- Phase 1b: Number of participants with disease response
- Phase 1a: Maximum Tolerated Dose (MTD)
- Phase 1b: Recommended dose of TTI-622 in combination with selected anticancer treatments
- Phase 1b: Recommended dose of TTI-622 as a single agent
- Number of participants with response assessments that show preliminary efficacy
- Sponsor
- Pfizer
- Start
- May 14, 2018
- Primary completion
- Jul 18, 2024
- Results posted
- No
- Registry record
- NCT03530683 · updated Sep 3, 2024